Absorbing Debate: Boston Scientific, Abbott Differ On Whether The Future Of Stents Is To Disappear
This article was originally published in Clinica
Executive Summary
Stents and scaffolds that could become the new standard tools for cath labs in the next several years were on display at the Transcatheter Cardiovascular Therapeutics conference in San Francisco earlier this month, but questions about the long-term effectiveness and economics of the devices were also prominent at the annual interventional cardiology meeting.
You may also be interested in...
FDA Approves Biotronik’s Thin-Strut Orsiro Coronary Stent
Bioresorbable-polymer, sirolimus-eluting Orsiro outperformed Abbott’s market-leading Xience durable-polymer, everolimus-eluting stent at the two-year follow-up in the BIOFLOW V trial. The company stresses that Orsiro is the first and only ultrathin drug-eluting stent to beat Xience in a randomized trial.
Robert Byrne: Absorb, Synergy, And The Future Of Coronary Stents
One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.